Skip to main content

Search

Reset all filters
513 Result(s)
Sort by

Maria Weber

Maria Weber

Lead Patient Safety Physician Maria Weber tells us about why she joined Boehringer Ingelheim, and the importance of patient centricity in everything she does.
RE-LY-trial-publication-10-year-anniversary

RE-LY-trial-publication-10-year-anniversary

Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
NEJM-IL-36-Phase-1-GPP-data

NEJM-IL-36-Phase-1-GPP-data

Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
emperor-reduced-heart-failure-toplineresults

emperor-reduced-heart-failure-toplineresults

Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
EMPRISE-interim-analysis

EMPRISE-interim-analysis

Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
EMPERIAL-heart-failure-toplineresults

EMPERIAL-heart-failure-toplineresults

Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
Co-creation with Communities

Co-creation with Communities

Making More Health has launched co-creation projects in Asia, Africa, Europe and other localities around the world with top social entrepreneurs.
Agreement-to-acquire-NBE-Therapeutics

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Biotherapeutics Discovery

Biotherapeutics Discovery

We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Be green Japan

Be green Japan

Boehringer Ingelheim's Yamagata site is gradually switching to a more sustainable energy supply.
Circular economy

Circular economy

Boehringer Ingelheim strives to use resources for as long as possible, process them for reuse or recycle them.
Collaboration to fight NCDs

Collaboration to fight NCDs

70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
FuturePack

FuturePack

Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
Outside the lab…inside the family

Outside the lab…inside the family

We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.